Status Awaiting development
Decision None selected
Process TA
ID number 3934

Timeline

Key events during the development of the guidance:

Date Update
17 August 2023 Please note, this appraisal has been scheduled as a single technology appraisal and will not be part of ID6234 at this time. If this changes, we will update stakeholders and the topic webpage.
17 July 2023 Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-July 2024. The appraisal timings will ensure the company is able to make a suitably comprehensive and robust submission.
27 February 2023 Please note that the evaluation of trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies ID3934, will now be conducted via ID6234 considering multiple treatments for non-small-cell lung cancer.
24 December 2021 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early June 2023 we will write to consultees and commentators about how they can get involved. The deadline for submissions is expected in approximately mid-August 2023.
22 July 2021 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-June 2022 when we will write to you about how you can get involved.

For further information on our processes and methods, please see our CHTE processes and methods manual